For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome
Take a look at our BETA site and see what we’ve done so far.
Search and browse selected products
Purchase these through your usual distributor
Keep your research moving forward
Updated June 2, 2023
We manufacture recombinant antibodies by cloning antibody genes into high-yield expression vectors and introducing these vectors into hosts.
Recombinant antibodies can succeed where other manufacturing methods often fall short. This method isn’t limited by low reproducibility and genetic drift, leading to variations in the final antibody, and more difficult targets such as toxins, nucleotides, and membrane-bound proteins become possible.
Our recombinant antibodies deliver many advantages, including batch-to-batch consistency, confirmed specificity, and ease of scalability, so that you can progress your research faster.
The advantages of recombinantly manufactured antibodies
Recombinant antibody production is controlled and made reliable using a unique set of genes. This leads to antibodies with high batch-to-batch consistency, meaning you can achieve the highly reproducible results and move your project forward faster.
Figure 1. Batch-to-batch reproducibility in the localization of PD-L1 in FFPE human placenta across five batches of our anti-PD-L1 [28-8] recombinant rabbit monoclonal antibody (ab205921). IHC was performed manually using a Biocare Decloaking Device and Universal HIER antigen retrieval reagent (ab208572). The primary antibody was incubated overnight at 4°C, followed by goat anti-rabbit secondary antibody and HRP-linked anti-goat polymer antibody (ab209101). DAB was used as a chromogen with a Hematoxylin counterstain.
KD value is a quantitative measure of antibody affinity. The lower the KD value, the higher the affinity of the antibody. Analysis of KD values of our recombinant anti-PDL1 antibody shows that its affinity remains high across five different batches (Table 1).
To ensure specificity, our recombinant antibodies undergo industry-leading validation. This includes over 3,800 with knock-out validation, so you can move your research forward faster.
And because the selection process for the desired clone occurs at both the hybridoma and recombinant cloning stages, we can select antibodies with the most favorable qualities for you.
Our recombinant antibodies have a remarkably high affinity, with KD values in the picomolar (10-10–10-12) range. High-affinity antibodies allow greater sensitivity in assays as they bind strongly to the antigen and maintain this bond better under difficult conditions compared to low-affinity antibodies.
The following example demonstrates the differences in specificity between recombinant antibodies and other antibody types:
Figure 2. Our recombinant anti-GRIM19 [EPR4471(2)] antibody (left) being tested on knock-out and wild-type samples against our monoclonal anti-GRIM19 [6E1BH7] antibody.
Recombinant manufacture relies on cloning antibody genes into expression vectors, so antibody expression can be carried out at any scale, with our guaranteed supply giving you continuity and peace of mind for projects of all sizes. This makes recombinant antibodies a great solution for long-term studies or using the same antibody across multiple samples.
Once the antibody-producing genes are isolated, high-throughput in vitro manufacture can be implemented. For antibodies generated using our phage display technology, even the gene of the antibody can be isolated with an animal-free procedure.
Recombinant multiclonal antibodies are a defined mixture of carefully selected individual recombinant monoclonal antibodies designed to recognize different epitopes on the same antigen. They are an ideal solution for applications where a polyclonal antibody would traditionally be used and provide the same specificity and reproducibility benefits as recombinant monoclonal antibodies.
The mix of antibodies that make the recombinant multiclonal antibodies is carefully controlled; each recombinant monoclonal antibody in the mix is developed from a defined set of genes that encode the antibodies with the desired characteristics. This ensures batch-to-batch consistency and reproducibility of results.
Our recombinant multiclonal range was awarded the CiteAb Innovation Award 2022.
Because recombinant multiclonal antibodies bind to multiple epitopes on the same target protein, they provide excellent sensitivity, making them suitable for when you need a reagent capable of analyzing low-abundance targets or detecting multiple post-translational modifications at once.
You can use multiclonals in any situation where a polyclonal would traditionally be used, but with additional benefits. Including:
Figure 3. Our recombinant anti-Histone H3 (citrulline R2 + R8 + R17) multiclonal antibody [RM1001], ab281584 (left), tested in multiple sample types in western blot against our polyclonal anti-Histone H3 (citrulline R2 + R8 + R17) antibody, ab5103.
Figure 4. Immunofluorescent analysis of mouse primary neural/glia cells labeling GFAP with our recombinant anti-GFAP multiclonal antibody, ab278054 (left), against our polyclonal anti-GFAP antibody, ab7260.
“This antibody gave strong, positive signal on the first try and has continued to work reproducibly for several months.” – Gabriel Galea, UCL GOS Institute of Child Health, using ab179484.
“Abcam’s anti-Synaptophysin antibody worked the first time. We were able to generate great images with a very low background using a confocal laser scan.” – Alexandre Magno, Universidade Federal de Minas Gerais (UFMG), using ab32127.
To find out more about what makes recombinantly manufactured antibodies different and how they can benefit your research, watch the short video below:
Find recombinant antibodies to key targets for your research area with our search filters:
2. Scroll down until you see the 'Research areas' filter on the left-hand side
3. Choose your research area of interest from the list to find highly validated recombinant antibodies to your key targets